As of 1 November 2021, the Therapeutic Goods Administration (TGA) will initiate a staged transition to electronic Common Technical Document-only (eCTD-only) for all prescription drugs.

As part of this transition, Australia will adopt best practice standards currently applied worldwide. Using eCTD benefits both sponsors and regulators and will improve lifecycle management and navigation capabilities.

The transition date to eCTD will be done in the following stages:

1 November 2021 - eCTD-Only Stage 1:

  • New Chemical Entity Medicine (Type A)
  • New Biological Entity Medicine (Type A)
  • New Biosimilar Medicine (Type A)
  • New Combination Medicine (Type B)

1 June 2022 - eCTD-Only Stage 2:

  • Extension of Indications Medicine (Type C)
  • Major Variation Medicine (Type F)
  • New Generic Product (Type D)

1 May 2023 - eCTD-Only Stage 3:

  • All remaining prescription medicine data, including master files

If a sponsor cannot meet the transition deadline(s), applications for waivers will be assessed by the TGA on a case-by-case basis. Most stage 1 and stage 2 applications are already submitted in eCTD format. Longer timeframes have been proposed to ensure that the mandate of the eCTD does not hinder the drugs in the development pipeline.

Do you look for a submission management solution or require help publishing your submissions? Contact us now!

Source: https://www.tga.gov.au/sponsors-advised-transition-ectd-only

Manage, publish and validate multi-region eSubmissions and product dossiers with EXTEDO´s eCTDmanager.

whiteWaveTop

Latest Blog Posts

500

The EMA published the FHIR Conceptual Data Model (CDM)

500

US FDA Adverse Event Reporting System (FAERS) Electronic Submissions

500

EMA Publishes New Timeline For DADI Project

500

US FDA Adopts ICH Clinical Trials Guideline with Exclusive Reference to E2B(R3) Standards